PMGC Holdings Inc. 8-K

What Happened

• PMGC Holdings Inc.’s wholly owned subsidiary, NorthStrive Defense Tech LLC, announced on June 30, 2026 that it entered into a Standard Exclusive License Agreement granting it a worldwide, non-transferable, exclusive license to U.S. Patent No. 12,291,334 and associated know‑how in the aerospace and defense field. The license allows NorthStrive to make, have made, use, sell and import licensed products and to grant sublicenses subject to the agreement’s terms. A copy of the agreement (Exhibit 10.1) was attached to the 8‑K; portions are redacted.

Key Details

• Effective Date: June 30, 2026.
• Patent: U.S. Patent No. 12,291,334 and related know‑how (defined in Appendix A of the agreement).
• Scope: Worldwide, exclusive license in the licensed field with the right to sublicense.
• Payments & Term: NorthStrive agreed to a non‑refundable license issue fee (amount redacted), annual maintenance fees until first Net Sales, sublicense payments, and royalties; royalty payments run on a product-by-product, country-by-country basis until the later of patent expiration or 12 years after first Net Sale in that country.
• Diligence & Reporting: NorthStrive must provide a development plan and annual written development reports (by January 15 each year) and meet specified diligence milestones; failure to substantially perform under the development plan or meet milestones may be a material breach (extensions may be requested).
• Termination Rights: NorthStrive may terminate (in whole or in part) without cause after the first anniversary with 60 days’ notice; Licensor may terminate for nonpayment within 30 days or repeated defaults, insolvency events, or uncured material breaches.

Why It Matters

• The agreement secures exclusive rights to a named patent and related know‑how in aerospace and defense for PMGC’s subsidiary, positioning the company to develop and commercialize products covered by that intellectual property.
• The deal includes upfront and ongoing financial obligations (issue fee, annual maintenance fees, royalties, and sublicense payments) and binding development milestones and reporting—items that can affect near‑term cash outflows and the timeline to potential revenue.
• Key financial terms (specific fee amounts) were redacted in the filed exhibit; investors should review the full Exhibit 10.1 in the 8‑K for the complete terms and monitor future disclosures for milestone progress and any sublicense or commercialization updates.